Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment
AT Ruffin, H Li, L Vujanovic, DP Zandberg… - Nature Reviews …, 2023 - nature.com
Targeted immunotherapy has improved patient survival in head and neck squamous cell
carcinoma (HNSCC), but less than 20% of patients produce a durable response to these …
carcinoma (HNSCC), but less than 20% of patients produce a durable response to these …
[HTML][HTML] Targeted therapy for head and neck cancer: Signaling pathways and clinical studies
Head and neck cancer (HNC) is malignant, genetically complex and difficult to treat and is
the sixth most frequent cancer, with tobacco, alcohol and human papillomavirus being major …
the sixth most frequent cancer, with tobacco, alcohol and human papillomavirus being major …
[HTML][HTML] Natural killer cell-related prognosis signature characterizes immune landscape and predicts prognosis of HNSCC
H Chi, X Xie, Y Yan, G Peng, DF Strohmer… - Frontiers in …, 2022 - frontiersin.org
Background: Head and neck squamous cell carcinoma (HNSCC), the most common head
and neck cancer, is highly aggressive and heterogeneous, resulting in variable prognoses …
and neck cancer, is highly aggressive and heterogeneous, resulting in variable prognoses …
[HTML][HTML] Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma …
L Yuan, GD Jia, XF Lv, SY Xie, SS Guo, DF Lin… - Nature …, 2023 - nature.com
Immunotherapy combined with antiangiogenic targeted therapy has improved the treatment
of certain solid tumors, but effective regimens remain elusive for refractory …
of certain solid tumors, but effective regimens remain elusive for refractory …
Novel systemic treatment modalities including immunotherapy and molecular targeted therapy for recurrent and metastatic head and neck squamous cell carcinoma
Head and neck squamous cell carcinomas (HNSCCs) are the sixth most common cancers
worldwide. More than half of patients with HNSCC eventually experience disease …
worldwide. More than half of patients with HNSCC eventually experience disease …
The key differences between human papillomavirus-positive and-negative head and neck cancers: biological and clinical implications
SF Powell, L Vu, WC Spanos, D Pyeon - Cancers, 2021 - mdpi.com
Simple Summary Head and neck cancer (HNC) is the sixth most common cancer, causing
almost half a million deaths worldwide every year. The two subtypes of HNC are distinctly …
almost half a million deaths worldwide every year. The two subtypes of HNC are distinctly …
Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma
Purpose: A phase II multi-institutional clinical trial was conducted to determine overall
survival (OS) in patients with recurrent and/or metastatic (R/M) head and neck squamous …
survival (OS) in patients with recurrent and/or metastatic (R/M) head and neck squamous …
Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): a phase II study with biomarker analysis
Purpose: EGFR pathway inhibition may promote anti–programmed cell death protein 1 (PD-
1) responses in preclinical models, but how EGFR inhibition affects tumor antigen …
1) responses in preclinical models, but how EGFR inhibition affects tumor antigen …
[HTML][HTML] Current perspectives on recurrent HPV-mediated oropharyngeal cancer
In the recent years, the prevalence of HPV-positive oropharyngeal squamous cell carcinoma
(OPSCC) has increased significantly. Currently, nearly 80-90% of all oropharynx tumors are …
(OPSCC) has increased significantly. Currently, nearly 80-90% of all oropharynx tumors are …
Immunotherapy and biomarker testing in recurrent and metastatic head and neck cancers: ASCO Guideline
PURPOSE To provide evidence-based recommendations for practicing physicians and
other health care providers on immunotherapy and biomarker testing for head and neck …
other health care providers on immunotherapy and biomarker testing for head and neck …